Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16226
Title: Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease
Austin Authors: Passey, Samantha L;Hansen, Michelle J;Bozinovski, Steven;McDonald, Christine F ;Holland, Anne E ;Vlahos, Ross
Affiliation: Austin Health, Heidelberg, Victoria, Australia
School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia
Lung Health Research Centre, Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, Victoria, Australia
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, the University of Melbourne, Institute for Breathing and Sleep, Heidelberg, Victoria, Australia
Department of Physiotherapy, La Trobe University and Alfred Health, Melbourne, Victoria, Australia
Issue Date: Oct-2016
metadata.dc.date: 2016-06-29
Publication information: Pharmacology & Therapeutics 2016; 166: 56-70
Abstract: Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that constitutes a major global health burden. A significant proportion of patients experience skeletal muscle wasting and loss of strength as a comorbidity of their COPD, a condition that severely impacts on their quality of life and survival. At present, the lung pathology is considered to be largely irreversible; however, the inherent adaptability of muscle tissue offers therapeutic opportunities to tackle muscle wasting and potentially reverse or delay the progression of this aspect of the disease, to improve patients' quality of life. Muscle wasting in COPD is complex, with contributions from a number of factors including inflammatory cytokines, oxidative stress, growth and anabolic hormones, nutritional status, and physical activity. In this review, we discuss current and emerging therapeutic approaches to treat muscle wasting in COPD, including a number of pharmacological therapies that are in development for muscle atrophy in other pathological states that could be of relevance for treating muscle wasting in COPD patients.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16226
DOI: 10.1016/j.pharmthera.2016.06.013
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27373503
Type: Journal Article
Subjects: Chronic obstructive pulmonary disease (COPD)
Comorbidities
Pulmonary rehabilitation
Skeletal muscle
Therapeutic strategies
Wasting
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
1-s2.0-S0163725816301036-main.pdf907.59 kBAdobe PDFThumbnail
View/Open
Show full item record

Download(s)

40
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.